Natera, Inc. (NTRA) scored on five pillars from its reported financial statements, and ranked against 212 Healthcare companies.
Natera, Inc. (NTRA) scores 4.2 out of 10 as of , computed from its reported financial statements. That reads as mixed quality. The reading rests on efficiency, and profitability is what holds it back.
One pillar, growth, is unscored because the filings behind it carry too little to judge. It is shown as a dash rather than a zero, and the overall score is the weighted average of what could be scored.
Data provided by Twelve Data. Scores are computed by Lemma Analysis from reported financials.
We cannot judge Natera, Inc. yet, because fewer than five years had both a return on capital and a cost of capital we could measure. This is not a “no”.
Quantitative signs of a moat, read from the filed statements. This is not a judgement of where it comes from (brand, network effects, switching costs). How Lemma measures a moat →
The Quality Score for NTRA stands at 4.2 out of 10 as of October 19, 2026, which puts Natera, Inc. in the mixed quality band. In this band one or two pillars are usually holding the score up while others drag it down, which the breakdown below makes visible. It rolls Natera, Inc.’s profitability, solvency, growth, efficiency and predictability into one number, each judged against the norms of its sector.
Ranked with the 212 Healthcare companies Lemma publishes, the score sits at the 47th percentile, just below the middle of the group. The median across the group is 4.4, and the top quarter begins at 6.0, so Natera, Inc. is in line with the typical company here.
On profitability, Natera, Inc. scores 1.2, a weak reading. Its peers have a median of 2.7 across 210 Healthcare companies, which places it well below them, at the 37th percentile. Weak profitability means the business converts less of its sales and capital into profit than its peers, which can come from thin pricing power, high costs or a temporary squeeze.
Natera, Inc.’s solvency score is 6.0 out of 10 (average). Against a median of 6.5 among 150 Healthcare companies, that is below the group and the 39th percentile. Leverage in the middle of the range is rarely a problem in good years, and it is worth watching how quickly it would tighten in a weak one.
Growth has no score for Natera, Inc. Fewer than half of the pillar’s metric weight could be computed from the reported statements, so it is drawn as a dash and left out of the overall rather than counted as a zero. For context, the median growth score across 107 Healthcare companies is 4.9. Growth needs at least three years of comparable annual statements, so a short or interrupted history leaves it blank.
Natera, Inc.’s efficiency score is 8.7 out of 10 (strong). Against a median of 6.0 among 200 Healthcare companies, that is well above the group and the 90th percentile. A strong efficiency reading usually shows up as healthy cash conversion: reported profit arriving as real cash rather than staying on the balance sheet.
On predictability, Natera, Inc. scores 2.8, a weak reading. Its peers have a median of 3.4 across 207 Healthcare companies, which places it below them, at the 45th percentile. Weak predictability means revenue or earnings have swung widely from year to year, so any single year’s figures are a less reliable guide.
The gap between Natera, Inc.’s best and worst pillar is wide: efficiency at 8.7 against profitability at 1.2, 7.5 points apart. An average of two readings this different deserves a closer look than the headline number. Leading with efficiency points to disciplined use of capital, a strength that compounds quietly. Weak profitability can be cyclical, so it helps to know whether margins are at a low point or a long-run level.
The pillar with the most room to move the score is profitability. If it rose to the median of Healthcare companies, 2.7, Natera, Inc.’s overall score would go from 4.2 to about 4.7. With one pillar unscored, the overall rests on 80 of the 100 weight points, spread across the four pillars that could be measured (the full set is profitability 25, solvency 20, growth 20, efficiency 15, predictability 20).
For a fair comparison, start with companies of a similar size: the Healthcare companies below are nearest to Natera, Inc. by market value, each scored on the same pillars.
How much profit the company generates from its capital and sales.
The company’s ability to service debt and meet its obligations.
How fast revenue, earnings and cash flow are compounding.
How well assets and earnings convert into cash and output.
How stable and consistent results have been over time.
Each metric is scored from 0 to 10 against sector-aware benchmarks, where higher is better. Metrics roll up into five pillars, and the pillars combine into the overall score using the weights shown. Sector-sensitive metrics are judged relative to peers in the same sector.
This score is a systematic, backward-looking read of reported fundamentals. It does not judge valuation, management quality, competitive moat, or future prospects, and can be distorted by one-off items or unusual accounting. Treat it as a starting point, not a recommendation.
Educational only. Not investment advice.
On this reading Natera, Inc. scores 4.2 out of 10, which reads as mixed quality. Its strongest pillar is efficiency, its weakest is profitability. Quality is not the same as a good investment: the score says nothing about the price you would pay.
Natera, Inc. ranks at the 47th percentile of the 212 Healthcare companies Lemma publishes a score for. The median there is 4.4 and the top quarter starts at 6.0, against Natera, Inc.’s 4.2.
Five pillars, each scored from 0 to 10 against sector-aware benchmarks and then weighted into one overall reading: profitability, solvency, growth, efficiency and predictability. Everything comes from reported financials, and nothing comes from price, sentiment or forecasts.
This page last changed on October 19, 2026. The score moves with the financial statements, so the page changes when a new filing moves the reading rather than on a schedule. Live figures for NTRA are in the app.
No. Quality and valuation are separate questions, and a good business at the wrong price is still a bad purchase. Score the business here, then price it with a DCF you control.
Inside Lemma Analysis the same five pillars run on every company we cover, with the metrics behind each one, current fundamentals, a DCF you control and a watchlist that tells you when the price catches up.
Free to start · No credit card